Augmentation of glucagon-like peptide-1 (GLP-1) receptor signalling is an established approach to the treatment of type 2 diabetes. However, endogenous GLP-1 and long-acting GLP-1 receptor analogues are degraded not only by dipeptidyl peptidase-4, but also by neprilysin. This observation raises the possibilities that endogenous GLP-1 contributes to the clinical effects of neprilysin inhibition and that patients concurrently treated with sacubitril/valsartan and incretin-based drugs may experience important drug-drug interactions. Specifically, potentiation of GLP-1 receptor signalling may underlie the antihyperglycaemic actions of sacubitril/valsartan. Neprilysin inhibitors may also be able to augment the effects of long-acting GLP-1 analogues to increase heart rate and myocardial cyclic AMP, and thus, potentiate these deleterious actions; if so, concomitant treatment with GLP-1 receptor agonists may limit the efficacy of neprilysin inhibitors in patients with both heart failure and diabetes. For patients not concurrently treated with GLP-1 analogues, the action of neprilysin to enhance the effects of GLP-1 may be particularly relevant in the brain, where augmentation of GLP-1 and other endogenous peptides may act to inhibit amyloid-induced neuroinflammation and cytotoxicity and improve memory formation and executive functioning. Experimentally, neprilysin inhibitors may also potentiate the effects of endogenous GLP-1 and GLP-1 receptor agonists on blood vessels and the kidney. The role of neprilysin in the metabolism of endogenous GLP-1 and long-acting GLP-1 analogues points to a range of potential pathophysiological effects that may be clinically relevant to patients with heart failure, with or without diabetes.
Glucagon-like peptide-1 (GLP-1) is an incretin that acts on the pancreas to stimulate the secretion of insulin from beta-cells and inhibit the secretion of glucagon from alpha-cells. The hormone's ability to lower blood glucose forms the basis of the use of incretin-based drugs in the treatment of type 2 diabetes. Long-acting GLP-1 analogues cause supraphysiological stimulation of the GLP-1 receptor, whereas dipeptidyl peptidase-4 (DPP-4) inhibitors block the breakdown of GLP-1 in the portal circulation following its release from the gastrointestinal tract, and in addition, can potentiate the actions of other endogenous peptides.
Interestingly, endogenous GLP-1 is degraded not only by DPP-4, but also by neprilysin. Both enzymes contribute equally to the breakdown of GLP-1, are increased in neprilysin-deficient mice, leading to improved glycaemic control. 2 Clinically, treatment with sacubitril/valsartan leads to increases in circulating GLP-1 as well as decrease in blood glucose in patients with heart failure. 3, 4 The effects of neprilysin inhibitors to potentiate GLP-1 receptor signalling are likely to be particularly exaggerated if patients are receiving an incretin-based drug. Because long-acting GLP-1 analogues are resistant to DPP-4, neprilysin emerges as a primary mechanism for their degradation. 5 Furthermore, if DPP-4 is pharmacologically blocked, neprilysin becomes the principal pathway for the inactivation of endogenous GLP-1. 6 Therefore, the consequences of neprilysin inhibition on GLP-1 receptor signalling are likely to be particularly important in patients taking incretin-based drugs ( Figure 1) . 
Interplay of glucagon-like peptide-1 signalling and neprilysin inhibition in the myocardium
When added to antagonists of the renin-angiotensin system, neprilysin inhibition reduces the risk of cardiovascular death and hospitalization for heart failure in patients with heart failure with a reduced ejection fraction. 7 Interestingly, the GLP-1 pathway is down-regulated in heart failure, and (like DPP-4 inhibition) neprilysin inhibition might restore normal GLP-1 receptor signalling. 8 Experimentally, such normalization may be accompanied by favourable effects on cardiac remodelling. 9 However, it seems unlikely that the benefits of neprilysin inhibition in patients with chronic heart failure are related to potentiation of endogenous GLP-1, since in patients with diabetes, enhanced GLP-1 receptor signalling (with either GLP-1 receptor agonists or DPP-4 inhibitors) does not reduce the risk of hospitalization for heart failure in large-scale trials.
10 -13 Furthermore, neprilysin inhibition in patients with heart failure is not accompanied by an increase in heart rate, which is seen with drugs that produce substantial stimulation of the GLP-1 receptor.
14 However, neprilysin inhibitors might lead to unexpected cardiovascular effects if they are given together with exogenously administered long-acting GLP-1 analogues. Even in the absence of neprilysin inhibition, supraphysiological stimulation of the GLP-1 receptor with long-acting analogues predictably leads to increases in heart rate, both in patients with type 2 diabetes as well as those with heart failure. postulated to explain this positive chronotropic effect, including a direct effect on the sinus node, 17,18 stimulation of the sympathetic nervous system and mediation of its effects on the heart, 19 -21 attenuation of vagal cardiac influences, 22, 23 and increases in cyclic AMP in the myocardium. 24 -27 GLP-1 receptor agonists produce positive inotropic effects in human atrial tissue 27 and enhance contractility in experimental cardiac dysfunction. 28 Furthermore, GLP-1 signalling increases cyclic AMP in cardiomyocytes and thereby promotes calcium currents. 24 -27 Treatment with long-acting GLP-1 analogues can worsen the clinical course of heart failure, 29, 30 although it is not clear whether this effect is related to the deleterious effects of an increase in heart rate or due to the calcium overload produced by increases in cyclic AMP. 31, 32 Additionally, when incretin signalling is already robustly augmented, further potentiation by neprilysin inhibition might enhance the injurious actions of cyclic AMP. This likelihood may be particularly high if inhibition of neprilysin acts to augment the effects of other endogenous peptides (adrenomedullin, vasoactive intestinal polypeptide or enkephalins) that increase myocardial cyclic AMP, independently of the actions of GLP-1. 33 -35 It has been argued that potentiation of GLP-1 receptor signalling does not adversely affect the development or clinical course of heart failure, because long-acting GLP-1 receptor agonists did not increase the risk of heart failure events in large-scale trials of patients with type 2 diabetes.
10,11 However, patients with type 2 diabetes are particularly prone to the development of heart failure with a preserved ejection fraction, 36 and it is possible that such patients are less susceptible than those with a reduced ejection fraction to the potentially deleterious cardiovascular actions of enhanced GLP-1 receptor signalling. Of note, the two clinical trials that reported worsening clinical status with liraglutide in patients with established heart failure only studied those with a reduced ejection fraction.
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Interplay of glucagon-like peptide-1 signalling and neprilysin inhibition in coronary arteries
In several large-scale clinical trials, treatment with long-acting GLP-1 analogues has been associated with a reduced risk of atherosclerotic ischaemic events (i.e. myocardial infarction and stroke). 10, 11 Numerous studies have demonstrated that signalling through the GLP-1 receptor has direct effects to inhibit the formation and promote the stability of atheromatous plaques. In experimental models, GLP-1 receptor agonists reduce the infiltration of macrophages, promote thicker fibrous caps and minimize smooth muscle proliferation. 37, 38 The net effect of these actions is a slowing of the atherosclerotic process, an attenuation of the inflammatory response in blood vessels, and a reduction in the likelihood of plaque rupture. However, potentiation of GLP-1 receptor signalling by inhibition of GLP-1 degradation (e.g. with DPP-4 inhibitors) did not have favourable effects on the risk of atherosclerotic vaso-occlusive events seen in large-scale trials. 12, 13 This lack of benefit may be related to the modest GLP-1 augmentation produced by DPP-4 inhibitors or an effect of DPP-4 inhibitors to potentiate the actions of pro-inflammatory chemokines that may promote plaque instability. 39, 40 The possibility that potentiation of GLP-1 signalling by neprilysin inhibition can reduce the risk of atherosclerotic thromboembolic events has been raised by a recently published analysis from the PARADIGM-HF trial, 41 which reported that, when compared with enalapril, treatment with sacubitril/valsartan reduced the risk of a composite of coronary ischaemic events. However, this risk was driven primarily by a beneficial effect on cardiovascular death; sacubitril/valsartan did not reduce the risk of non-fatal myocardial infarction or hospitalization for myocardial ischaemia or the need for coronary revascularization. Although sacubitril/valsartan reduced the risk of sudden death, 42 it is not clear whether this benefit reflect a favourable effect on the progression of left ventricular dysfunction or the prevention of clinically silent coronary occlusions. 41, 43 However, the finding of a lack of effect on the risk of cerebrovascular events (in addition to the absence of an apparent effect on non-fatal coronary events) 41 suggests that neprilysin inhibition is unlikely to influence the growth or cause stabilization of atherosclerotic plaques, either by potentiating the action of GLP-1 or of other endogenous peptides.
Interplay of glucagon-like peptide-1 signalling and neprilysin inhibition in the kidney
Glucagon-like peptide-1 receptor signalling inhibits the reabsorption of sodium in the proximal renal tubules, thereby enhancing its distal delivery to the macula densa; the resulting activation of tubuloglomerular feedback would be expected to cause afferent arteriolar vasoconstriction and amelioration of glomerular hyperfiltration. 44 -46 This action may explain why a long-acting GLP-1 receptor analogue reduced urinary albumin excretion and exerted favourable effects on the clinical course of diabetic nephropathy in a large-scale clinical trial. 46 Interestingly, neprilysin inhibition may also inhibit proximal tubular sodium reabsorption, enhance the delivery of sodium to the macula densa and potentiate tubuloglomerular feedback. However, these effects are likely related to its action to potentiate the effects of cyclic GMP in the kidney, which not only acts on the proximal tubule, 47 but also directly augments the ability of the macula densa to modulate afferent arteriolar tone. 48, 49 Long-term neprilysin inhibition appears to be have favourable effects on the course of renal disease in diabetic patients with heart failure, 50 and it is possible that enhanced signalling through the GLP-1 receptor pathway contributes to these benefits. However, it is noteworthy that neprilysin inhibition has been accompanied by increases (not decreases) in albuminuria, 51 presumably because of an effect of potentiated cyclic GMP to inhibit renal tubular protein reabsorption. 52 
Interplay of glucagon-like peptide-1 signalling and neprilysin inhibition in the brain
Endogenous GLP-1 plays an important homeostatic role in neuronal health and cognition. After its synthesis, GLP-1 crosses the blood-brain barrier and stimulates the metabolism, growth and repair of neurons and minimizes oxidative injury and inflammation. 55 Mice that lack the GLP-1 receptor are deficient in learning and in neuroprotection, 56 and defects in endogenous GLP-1 signalling have been implicated in the progressive loss of neurons that characterizes neurodegenerative disorders. 57 In laboratory models of brain injury and ischaemia, potentiation of GLP-1 receptor signalling reduces cerebral infarct size and neuronal inflammation, promotes progenitor cell proliferation, and improves cognition. 58, 59 In experimental models of Alzheimer's disease, inhibition of GLP-1 degradation minimizes amyloid-beta deposition, tau protein phosphorylation and neuroinflammatory markers; reduces the neurotoxicity of beta-amyloid deposits; and ameliorates the impairment of synaptic plasticity and memory formation. 60, 61 In clinical studies, drugs that inhibit GLP-1 breakdown have had favourable effects on cognition in elderly patients with or at risk of Alzheimer's disease, even in the absence of pre-existing glucose intolerance. 62 Could neprilysin inhibition potentiate the effects of endogenous GLP-1 and thereby improve cognition? Interestingly, some researchers have been concerned that neprilysin inhibition might impair cognitive function, because neprilysin is among the enzymes that contribute to the clearance of amyloid in the central nervous system; 63 amyloid-beta is increased in the brains of neprilysin-deficient mice. 64 However, despite an increase in the level of amyloid-beta in the brain, mice that are genetically deficient in neprilysin do not exhibit an increase in amyloid-beta deposits, and neurocognitive function improves; this benefit has been attributed to potentiation of the neuroprotective effects of endogenous GLP-1. 65 Furthermore, in addition to GLP-1, other endogenous peptides that are enhanced by neprilysin inhibition are known to ameliorate neuronal injury in the laboratory. Specifically, adrenomedullin has established neuroprotective effects in experimental brain injury, 66 and both vasoactive intestinal polypeptide and enkephalins have been shown to reduce the accumulation and cytotoxicity of amyloid-beta in neurons. 67, 68 An action of neprilysin inhibition to simultaneously augment all of these peptides may yield synergistic effects to minimize neurodegeneration. Such a mechanism may explain why people who carry the neprilysin loss-of-function mutation do not exhibit neurocognitive deficits 69 and why in two large-scale heart failure trials, long-term neprilysin inhibition was not associated with dementia or memory impairment.
to enhance the actions of endogenous GLP-1 may be important in the brain, where it may act to minimize the accumulation of amyloid-beta aggregates, impair amyloid-related inflammation and cytotoxicity, and improve memory formation and executive functioning. However, neprilysin is also the primary pathway responsible for terminating the action of long-acting GLP-1 analogues used in treating type 2 diabetes. If these agents exert deleterious cardiac effects through an action on heart rate or myocardial cyclic AMP, potentiation of these actions by sacubitril/valsartan may limit or negate the benefits of neprilysin inhibition in patients with both heart failure and diabetes. Studies to evaluate the possibility of clinically important drug-drug interactions (if any) are needed to ensure the safe use of these valuable medications. Conflict of interest: M.P. has recently consulted for Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Cardiorentis, Celyad, Daiichi Sankyo, Gilead, Novartis, NovoNordisk, Relypsa, Sanofi, Takeda, and ZS Pharma.
